Sep 28, 2025, 11:29 PM ETFireside Chat, Interview

Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

Eli Lilly's market capitalization has increased approximately 860% since CEO David Ricks took the helm.
The company's stock price has risen by over 1,000% during Ricks' tenure.
In Q2 2024, global sales of the GLP-1 drug Mounjaro (tirzepatide) surpassed $8.1 billion, making it the best-selling drug of all time.
Mounjaro's revenue is currently growing at a rate of 80% year-over-year.
Approximately 20 million people globally are estimated to be using prescription GLP-1 medications.
The company spent $14.2 billion on R&D this year, representing 25% of its sales revenue.
Eli Lilly employs approximately 4,200 PhD scientists, a workforce size comparable to the combined research staff of MIT and Harvard.

The company launched its first GLP-1 drug in 2006 for diabetes, with the weight loss side effect noted as early as 2007.
Tirzepatide (Mounjaro/Zepbound) was created in 2014 by combining GLP-1 with a second peptide, GIP.
Eli Lilly is developing a non-injectable pill version of the drug, expected to launch in the coming year.
The oral formulation aims to facilitate insurance reimbursement, which currently favors conditions requiring lifelong treatment like hypertension.
Eli Lilly projects single-digit price deflation (5% to 10% annually) in the GLP-1 category over time.
The company has launched over 100 clinical studies exploring GLP-1 applications beyond weight loss.
Current research includes trials for bipolar disorder and major depressive disorder, with a dedicated brain-targeting molecule expected in 3–4 years.
Studies have observed secondary benefits including reduced smoking cessation rates, lower gambling addiction, and decreased online shopping compulsions.
Mounjaro demonstrated a 93% reduction in the conversion rate from pre-diabetes to diabetes in trials.
Eli Lilly recently acquired a gene therapy company in June to diversify its portfolio.

To address global supply shortages and gray market competition, Eli Lilly is constructing six new manufacturing plants in the U.S., with four more to be announced soon.
These construction projects are expected to create 20,000 jobs during the build phase and 5,000–6,000 permanent manufacturing jobs.
The company plans to become a net exporter of these injectable drugs once capacity scales.
Ricks noted that while China subsidizes "swarm model" follow-on biotechs, replicating Eli Lilly's complex injectable supply chain remains difficult for competitors.
The U.S. patent "first-to-file" system, enacted in 2011, exposes chemical structures early, which Ricks acknowledged helps Chinese firms use AI to reverse-engineer derivatives outside patent scope.

Out-of-pocket costs for patients have been reduced from an initial $1,000 to $4.99 through the company's direct assistance programs.
Ricks argues against aggressive price cuts (e.g., to $100) to avoid stifling the incentive to create the next generation of medicines.
Eli Lilly views itself as an R&D engine rather than a cash-return franchise, intending to reinvest profits into solving diseases with no existing cures.
The company is transitioning away from its current PBM provider to a more transparent alternative to align with business interests and service quality.
Ricks expressed skepticism regarding the current state of U.S. university research funding, suggesting the NIH grant model may suffer from "back-scratching" and a lack of strategic competition.
The CEO supports reducing direct-to-consumer TV drug advertising, citing FDA regulations that necessitate scrolling side-effect disclaimers which degrade ad quality.

The biotech sector faces a "dumpster fire" of capital availability, with new investment checks falling from a peak of $20 billion annually to roughly $5 billion.
Capital crowding out by AI and faster-cycle technologies, combined with a high rate of biotech IPOs trading below cash, has depressed valuations.
Eli Lilly reports acquiring deals approximately every two weeks, though most are small-scale acquisitions of external innovation.
The CEO identified brain diseases as the next major opportunity, noting that 40% of global suffering is attributed to conditions like dementia and depression where current drug efficacy is low.

CEO David Ricks personally utilized GLP-1 therapy to lose 41 pounds (dropping from 213 to 172 lbs) over three years.
Ricks cited "food noise" (constant hunger thoughts) as a primary motivator, noting that low-dose usage helps reset his relationship with food after discontinuation.
The CEO declined to recommend prophylactic use for healthy individuals, stating clinical data currently only supports use for disease states or pre-disease states.
Ricks emphasized four pillars of his personal health routine: evidence, sleep, plant-based nutrition, and social relationships.
While acknowledging the biohacking community's interest in peptides like BPC-157, Ricks stated the company strictly adheres to FDA-approved clinical pathways.